三种抗菌药物治疗儿童社区获得性肺炎的成本-效果分析

Cost-effectiveness Analysis of Three Kinds of Antibiotics in the Treatment of Pediatric Bronchopneumonia

目的用药物经济学的方法对三种抗菌药物治疗儿童社区获得性肺炎的方案进行分析,为临床用药提供参考。方法采用回顾性研究方法,根据用药方案不同将185例支气管肺炎的患儿分为A组(头孢噻肟钠)56例、B组(美洛西林钠舒巴坦钠)74例、C组(拉氧头孢钠)55例,采用成本-效果分析法对三种抗菌药物进行药物经济学评价。结果A、B、C 3组的有效率分别为92.86%、95.95%、96.36%,总治疗成本分别为3793.20元、3347.82元、3984.13元,成本/效果比(C/E)分别为42.71、36.33、43.73。其中,B组治疗方案的成本最低,C/E最小。结论B组(美洛西林钠舒巴坦钠)是用于治疗儿童社区获得性肺炎的最经济有效的治疗方案。

OBJECTIVE To evaluate the pharmacoeconomics of three kinds of antibiotics in the treatment of pediatric bronchopneumonia,and to provide reference for rational drug use in the clinic.METHODS By retrospective study,185 children with broncho-pneumonia were divided into groups A,B and Caccording to different therapy regimens.There were 56,74,55 cases in groups A,B,C,and they were treated by Cefotaximesodium,Mezlocillin sodium/sulbact amsodium,Latamoxef sodium,respectively.The pharmacoeconomics of therapy regimens in group A,B,C were evaluated by cost-effectiveness analysis.RESULTS The effective rates of groups A,B,C were 92.86%,95.95%,96.36%,respectively.The treatment cost of those groups were 3793.20,3347.82,3984.13 yuan,respectively.The cost/effectiveness(C/E)ratio of those groups were 42.71,36.33,43.73,respectively.The treatment cost of group B was the smallest,so was the C/E.CONCLUSION Mezlocillin sodium/sulbactam sodium is the best treatment for pediatric bronchopneumonia.